LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to ...

An array of pharmaceutical pills with the company's logo on the bottle. Eli Lilly and Company ... human pharmaceutical ...

Eli Lilly and Company (NYSE:LLY) has a strong presence in oncology, immunology, and neuroscience, and is investing in new technologies and partnerships to drive innovation in these areas.

Eli Lilly has established itself as a frontrunner in the biopharmaceutical industry, with a strong focus on diabetes, oncology, immunology, and neuroscience. The company's recent financial performance ...

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh. The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a ...

Eli Lilly and Co.’s approval for Omvoh to ... Dr. Mark Genovese, senior vice president of Lilly Immunology development, said Omvoh offers patients with Crohn’s another option to deal with ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Dr. Gehchan brings 20 years of U.S. and international experience across multiple therapeutic areas, including immunology, as both an accomplished pharmaceutical executive and a physician to this newly ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... lepodisiran for cardiovascular disease and a number of other compounds in immunology and oncology. Such a breadth of this pipeline, along with ...